Clinical Trial Update: Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating AZD5363 in combination with paclitaxel for advanced gastric adenocarcinoma with PIK3CA mutation or amplification; study status complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma
• Gastric Cancer

Drugs mentioned

• AZD5363 (capivasertib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Samsung Medical Center | Conditions: Advanced Gastric Cancer | Phase 2 | Status: COMPLETED